Prescribed Reading: Neuro's comeback tour
BioPharma Dive | March 16, 2018
Biopharma is a complex, rapidly evolving industry that is highly regulated and closely watched and that means there is constant news. Here's a closer look at the clinical trials, M&A, cool science and regulations that are driving the industry this week. It was all about the neuroscience space this week, led by shifting fortunes for the CGRP inhibitor class. While Novartis AG and Amgen Inc., as well as Eli Lilly Co., all await regulatory decisions on their respective CGRP inhibitors, other players in the migraine space were shaking up the landscape.